Agonist-Dependent Coupling of the Promiscuous Adenosine A2B Receptor to Gα Protein Subunits
- 3 May 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (5) , 373-386
Abstract
The adenosine A2B receptor (A2BAR) belongs to the rhodopsin-like G protein-coupled receptor (GPCR) family. It is upregulated under hypoxic conditions, in inflammation and cancer. Previous studies indicated the coupling of the A2BAR to different G proteins, mainly Gs, but in some cases Gq/11 or Gi, depending on the cell type. We have now utilized novel technologies, (i) heterologous expression of individual members of the Gαq/11 protein family (Gαq, Gα11, Gα14, and Gα15) in Gαq/11 knockout cells, and (ii) the TRUPATH platform, allowing the direct observation of Gα protein activation for each of the Gα subunits by bioluminescence resonance energy transfer (BRET) measurements. Three structurally diverse A2BAR agonists were studied: the cognate agonist adenosine, its metabolically stable analog NECA, and the non-nucleosidic partial agonist BAY 60-6583. Adenosine and NECA activated most members of all four Gα protein families (Gαs, Gαq/11, Gαi, and Gα12/13). Significant differences in potencies and efficacies were observed; the highest efficacies were determined at the Gα15, Gαs, and Gα12 proteins, and for NECA additionally at the Gαi2 protein. In contrast, the partial agonist BAY 60-6583 only activated Gα15, Gαs, and Gα12 proteins. Adenosine deaminase, an allosteric modulator of ARs, selectively increased the potency and efficacy of NECA and BAY 60-6583 at the Gα15 protein, while it had no effect or decreased efficacy at the other Gα proteins. We conclude that the A2BAR is preferably coupled to the Gα15, Gαs, and Gα12 proteins. Upon upregulation of receptor or Gα protein expression, coupling to further Gα proteins likely occurs. Importantly, different agonists can display different activation profiles.Keywords
Funding Information
- Bundesministerium f?r Bildung und Forschung
- Takeda Science Foundation
- Daiichi Sankyo Foundation of Life Science
- Deutsche Forschungsgemeinschaft (FOR2372, GRK1328)
- Japan Agency for Medical Research and Development (JP20am0101095, JP20gm0010004)
- European Cooperation in Science and Technology (CA18133)
- Japan Society for the Promotion of Science (21H04791, 21H05113)
- Japan Science and Technology Agency (JPMJFR215T)
- Uehara Memorial Foundation
- Kementerian Keuangan Republik Indonesia
This publication has 62 references indexed in Scilit:
- Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor ImmunoescapeJournal of Biomedicine and Biotechnology, 2012
- A2Badenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive toPertussistoxinBritish Journal of Pharmacology, 2011
- Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysisBMC Genomics, 2011
- A2badenosine receptors can change their spotsBritish Journal of Pharmacology, 2010
- 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2BReceptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype SpecificityJournal of Medicinal Chemistry, 2009
- Contribution of Adenosine A2B Receptors to Inflammatory Parameters of Experimental ColitisThe Journal of Immunology, 2009
- Regulation and Physiological Functions of G12/13-Mediated Signaling PathwaysNeurosignals, 2009
- Probing the activation-promoted structural rearrangements in preassembled receptor–G protein complexesNature Structural & Molecular Biology, 2006
- Improving Potency, Selectivity, and Water Solubility of Adenosine A1Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinedionesChemMedChem, 2006
- Heterotrimeric G‐proteins: a short historyBritish Journal of Pharmacology, 2006